Ordinary Index Rebalancing in the Solactive Pharma Breakthrough Value Index | March 2022

In the ordinary rebalance the following composition will be implemented effective open 21.03.2022:

ABBVIE INC
AMICUS THERAPEUTICS INC
BIOGEN INC
BIOMARIN PHARMACEUTICAL INC
BRISTOL-MYERS SQUIBB CO
CHUGAI PHARMACEUTICAL CO LTD ORD
CLINUVEL PHARMACEUTICALS LTD
CSL LTD ORD
EMERGENT BIOSOLUTIONS INC
GENMAB A/S
GRIFOLS SA CLASS A
HALOZYME THERAPEUTICS INC
HORIZON THERAPEUTICS PLC
INCYTE CORP
IONIS PHARMACEUTICALS INC
IPSEN SA
JAZZ PHARMACEUTICALS PLC
JOHNSON & JOHNSON
KYOWA KIRIN CO LTD
NIPPON SHINYAKU CO LTD
NOVARTIS AG-ADR
OXFORD BIOMEDICA PLC
PHARMA MAR SA
PTC THERAPEUTICS INC
ROCHE HOLDING AG
SANOFI SA
SAREPTA THERAPEUTICS INC
SINO BIOPHARMACEUTICAL LTD ORD
SUPERNUS PHARMACEUTICALS INC
SWEDISH ORPHAN BIOVITRUM AB
TAKEDA PHARMACEUTICAL
ULTRAGENYX PHARMACEUTICAL INC
UNITED THERAPEUTICS CORP
VERTEX PHARMACEUTICALS INC